About 1 in 4 healthy adults over 70 have a detectable blood cell mutation called CHIP at a moderate level (2–10%), which is linked to a higher chance of serious bleeding, but not to heart attacks or strokes.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A meta-analysis could confirm whether the 23% prevalence and 24% bleeding risk increase are consistent across populations with standardized CHIP detection methods.
A systematic review and meta-analysis of 10+ prospective cohorts using uniform sequencing (≥2% VAF) in adults aged 65+, reporting bleeding incidence and MACE rates, with subgroup analysis by VAF tier and adjustment for age, sex, and anticoagulant use.
An RCT could test whether suppressing CHIP clones reduces bleeding incidence, establishing a causal pathway.
A double-blind RCT of 1,000 adults aged 70+ with CHIP (VAF 2–10%) randomized to a targeted clonal suppressor (e.g., JAK2 inhibitor) vs. placebo for 3 years, with primary endpoint: incidence of ISTH-defined major bleeding.
A prospective cohort could validate the 23% prevalence and 24% bleeding risk increase over time in a different population.
A multicenter prospective cohort of 15,000 adults aged 70+ without CVD, with baseline CHIP sequencing (VAF 2–10%), annual follow-up for 7 years, and blinded adjudication of bleeding events, adjusting for aspirin use, hypertension, and renal function.
A cross-sectional study could estimate the prevalence of moderate CHIP and its co-occurrence with bleeding in a single population.
A single-timepoint survey of 6,000 adults aged 70+ with known bleeding history and CHIP status (VAF 2–10%) via sequencing, comparing prevalence between those with and without recent bleeding.
Case reports could describe individuals with moderate CHIP and unexplained bleeding, but cannot quantify population risk.
A series of 15 case reports of adults aged 70+ with VAF 2–10% and unexplained major bleeding, documenting mutation profile and clinical course.